Plenvu Shortage: A Provider Briefing for 2026

Bowel preparation adherence remains one of the most significant modifiable factors affecting colonoscopy quality. Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution) has become a preferred prep in many gastroenterology practices due to its low 1-liter volume and improved patient tolerability. However, intermittent availability issues have created workflow challenges for providers and confusion for patients.

This briefing provides an updated assessment of Plenvu availability, prescribing considerations, and practical tools for managing bowel prep access in your practice.

Current Shortage Status and Timeline

As of early 2026, Plenvu is not listed on the FDA Drug Shortage Database. Salix Pharmaceuticals (Bausch Health) has not announced any manufacturing disruptions or supply limitations for the product.

However, reports from clinical practices indicate that patients continue to encounter out-of-stock situations at retail pharmacies. This is a distribution and stocking issue rather than a true manufacturing shortage — an important distinction when counseling patients and managing expectations.

Historical Context

Plenvu received FDA approval in May 2018 and was commercially launched in September 2018. Since then, it has not appeared on the FDA's drug shortage list. Periodic availability issues have been driven by:

• Increasing colonoscopy volumes following the 2021 USPSTF recommendation to begin screening at age 45
• Single-source manufacturing (no generic competitors until patent expiration, estimated September 2033)
• Pharmacy inventory management systems that deprioritize intermittently dispensed medications
• Broader pharmaceutical supply chain disruptions affecting distribution networks

Prescribing Implications

The practical impact on your practice includes:

Patient Adherence and Procedure Cancellations

When patients cannot find their prescribed prep, the most common outcome is a phone call to your office — or worse, a missed or poorly prepped procedure. Patients who scramble for a last-minute alternative may not follow preparation instructions correctly, potentially compromising bowel cleansing quality.

Formulary and Insurance Considerations

Plenvu is generally covered by commercial insurance plans and Medicare Part D when prescribed for a medically necessary colonoscopy. However, coverage varies:

• Some plans require prior authorization
• Formulary placement may favor lower-cost alternatives like generic PEG-based preps (GoLYTELY generics)
• Step therapy requirements may necessitate trial of a formulary-preferred agent first

Prescribing Flexibility

Consider including an alternative prep on the patient's colonoscopy instruction sheet or prescribing a backup option proactively. This prevents delays and gives patients a fallback if their primary prep is unavailable.

Availability Picture in 2026

The current availability landscape for Plenvu and key alternatives:

• Plenvu: Generally available but inconsistently stocked at retail pharmacies. Independent pharmacies and specialty pharmacy networks tend to have more reliable access.
• Suprep: Widely available. Sulfate-based, low-volume (two 6-oz bottles). No generic available.
• Sutab: Growing market share. Tablet-based prep gaining preference among patients who struggle with liquid solutions.
• GoLYTELY/NuLYTELY: Universally available in generic form. The fallback option when branded low-volume preps cannot be obtained.
• Clenpiq: Available. Ultra-low volume (two 5.4-oz doses). Contains sodium picosulfate (stimulant laxative component).

Cost and Access Considerations

Understanding cost helps when discussing options with patients:

• Plenvu cash price: $150–$210 per kit
• Plenvu with co-pay card: As low as $0 (commercially insured) or $70 (Medicare Part D)
• Suprep cash price: $150–$200
• Sutab cash price: $75–$150
• Generic GoLYTELY: $10–$30
• Clenpiq cash price: $150–$250

For patients facing cost barriers, the Bausch Health Patient Assistance Program provides Plenvu at no cost to qualifying uninsured or underinsured patients. Discount card services such as SingleCare offer Plenvu for approximately $152.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that helps you and your staff check real-time Plenvu availability at pharmacies near your patients. This can be integrated into your pre-procedure workflow to identify in-stock pharmacies before the patient leaves your office.

Proactive Prescription Management

Consider these workflow optimizations:

1. Prescribe early: Send the Plenvu prescription at the time of scheduling, not at the pre-procedure visit, giving patients maximum lead time.
2. Include alternatives on prep sheets: List a primary and backup prep on your colonoscopy instruction sheet so patients know their options.
3. Partner with pharmacies: Develop relationships with 2-3 pharmacies (including at least one independent) that reliably stock colonoscopy preps.
4. Use the co-pay program: Provide patients with information about the Plenvu Co-Pay Savings Program at the time of prescribing to reduce cost-related fill abandonment.
5. Direct patients to Medfinder: Recommend medfinder.com as a resource for checking pharmacy availability.

Patient Education Resources

Direct patients to these resources for self-service support:

• How to find Plenvu in stock near you
• Alternatives to Plenvu
• How to save money on Plenvu
• Plenvu side effects: what to expect

Looking Ahead

No generic Plenvu is expected until approximately September 2033. In the interim, the colonoscopy prep market is likely to continue evolving:

• Sutab's growing adoption may shift prescribing patterns away from liquid-based preps
• Potential new formulations and prep products are in various stages of development
• Increasing colonoscopy volumes (driven by expanded screening guidelines and a growing eligible population) will sustain demand for all prep products

The most effective strategy for your practice is a flexible approach: be prepared to prescribe alternatives, equip patients with tools to find their prep, and build pharmacy partnerships that improve access.

Final Thoughts

Plenvu remains an excellent low-volume bowel prep option with strong patient satisfaction data. While it is not in formal shortage, real-world access issues require proactive management by providers. Leveraging tools like Medfinder, maintaining prescribing flexibility, and educating patients about alternatives will help ensure your colonoscopy schedule runs smoothly regardless of any individual product's availability.

For a complementary practice-focused guide, see how to help your patients find Plenvu in stock.